{
    "2021-12-21": [
        [
            {
                "time": "2023-12-21",
                "original_text": "恒瑞医药董事长孙飘扬：医药企业应关注百姓未被满足的多样化临床需求",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "孙飘扬",
                        "临床需求",
                        "医药企业"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-12-21",
                "original_text": "29亿美元重磅交易！高瓴重仓股领先下一个PD-1争夺战，恒瑞会跟进吗？",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "高瓴资本",
                        "PD-1",
                        "交易"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-12-21",
                "original_text": "新药 | 瑛派药业ATR抑制剂IMP9064申报临床，阿斯利康、拜耳、恒瑞医药等积极布局",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "瑛派药业",
                        "ATR抑制剂",
                        "新药"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-12-21",
                "original_text": "恒瑞医药：四纵一横的营销体系架构布局，使公司产品的推广更加专注、专业",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "营销体系",
                        "产品推广"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-12-21",
                "original_text": "恒瑞医药：公司未被美国列入实体清单中",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "实体清单",
                        "美国"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-12-21",
                "original_text": "业绩放缓 研发却丝毫不松懈 恒瑞医药创新药期待“开花结果”",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "业绩放缓",
                        "研发",
                        "创新药"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-12-20",
                "original_text": "A股融资融券日报：两融余额减少40.23亿元（12月20日）",
                "features": {
                    "keywords": [
                        "A股",
                        "融资融券",
                        "两融余额"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}